Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients. The company is also developing a HIF-based portfolio of product candidates, such as AKB-5169, a preclinical compound for the treatment of inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds internationally. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-871-2098
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$177.98 million
Profitability
Miscellaneous
Employees114
OptionableOptionable
Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions
What is Akebia Therapeutics' stock symbol?
Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."
How were Akebia Therapeutics' earnings last quarter?
Akebia Therapeutics Inc (NASDAQ:AKBA) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.18. The biopharmaceutical company earned $53.17 million during the quarter, compared to analyst estimates of $39.71 million. Akebia Therapeutics had a negative return on equity of 45.61% and a negative net margin of 30.29%. View Akebia Therapeutics' Earnings History.
When is Akebia Therapeutics' next earnings date?
What price target have analysts set for AKBA?
5 Wall Street analysts have issued 12 month target prices for Akebia Therapeutics' stock. Their predictions range from $9.00 to $22.00. On average, they expect Akebia Therapeutics' stock price to reach $16.1667 in the next year. This suggests a possible upside of 153.0% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.
What is the consensus analysts' recommendation for Akebia Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.
What are Wall Street analysts saying about Akebia Therapeutics stock?
Here are some recent quotes from research analysts about Akebia Therapeutics stock:
- 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/16/2019)
- 2. Mizuho analysts commented, "We expect Akebia to compete with two other products within next-generation (HIF-PHI) anemia drugs and we believe order of market entry will be; 1) Fibrogen (FGEN, Buy, $74 PT)’s roxadustat, 2) Akebia’s vadadustat, and 3) GlaxoSmithKline (GSK, Not-rated)’s daprodustat, which we think is ~ 6 months behind vadadustat." (12/4/2018)
- 3. HC Wainwright analysts commented, "Our $42 price target is based on a 13-year DCF analysis of the Hemophilia B (65% (5% POS). We anticipate Hemophilia B commercial launch during 2021 and model risk-adjusted peak sales of roughly $820M during 2028. We assume a launch price of $772.5K (durability >5 years), and at peak, we estimate about 775 patients in the U.S. and approximately 1,050 patients in the developed markets who would have received uniQure’s gene therapy, which represents an 50% of the overall commercial opportunity." (6/29/2018)
Has Akebia Therapeutics been receiving favorable news coverage?
Media stories about AKBA stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Akebia Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting Akebia Therapeutics?
Akebia Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 5,625,043 shares, a drop of 61.0% from the December 14th total of 14,427,584 shares. Based on an average trading volume of 1,440,325 shares, the short-interest ratio is presently 3.9 days. Approximately 5.5% of the company's shares are short sold. View Akebia Therapeutics' Current Options Chain.
Who are some of Akebia Therapeutics' key competitors?
Some companies that are related to Akebia Therapeutics include Cambrex (CBM), Arrowhead Pharmaceuticals (ARWR), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Wave Life Sciences (WVE), TherapeuticsMD (TXMD), Myovant Sciences (MYOV), Clovis Oncology (CLVS), Esperion Therapeutics (ESPR), Uniqure (QURE), Kiniksa Pharmaceuticals (KNSA), Spectrum Pharmaceuticals (SPPI), Rhythm Pharmaceuticals (RYTM) and Amphastar Pharmaceuticals (AMPH).
Who are Akebia Therapeutics' key executives?
Akebia Therapeutics' management team includes the folowing people:
- Mr. John P. Butler, CEO, Pres & Director (Age 55)
- Mr. Michel Dahan, Sr. VP & Chief Bus. Officer (Age 40)
- Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)
- Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)
- Ms. Nicole R. Hadas, Sr. VP, Gen. Counsel & Sec. (Age 46)
Who are Akebia Therapeutics' major shareholders?
Akebia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.05%) and Bristol Advisors LLC (0.03%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.
Which institutional investors are buying Akebia Therapeutics stock?
How do I buy shares of Akebia Therapeutics?
Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akebia Therapeutics' stock price today?
One share of AKBA stock can currently be purchased for approximately $6.39.
How big of a company is Akebia Therapeutics?
Akebia Therapeutics has a market capitalization of $359.47 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.
What is Akebia Therapeutics' official website?
How can I contact Akebia Therapeutics?
Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]
MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.
